Siddiq Afshan, Khan Rafeeq Alam, Baig Sadia Ghousia
Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Karachi-75270, Pakistan.
J Pharm Bioallied Sci. 2011 Apr;3(2):306-9. doi: 10.4103/0975-7406.80767.
Increased risk of coronary artery disease in diabetic persons is associated with increased level of lipoproteins. Usually, such risks are reverted with glycemic control by antidiabetic medicines in Type I diabetes millitus. However, in Type II diabetes mellitus lipid values can be improved using antidiabetics but still the risk of coronary artery disease remains. The initial approach for reducing lipid contents in diabetic patients should include glycemic control, diet, weight loss, and exercise. But if it fails then lipid-lowering agents like fibrate and HMG CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase) inhibitors should work effectively. In the present study results of atorvastatin compared with biguanides proved atorvastatin as a more effective lipid-lowering agent along with antidiabetic activity so it can effectively help in reducing the risk of cardiovascular disease (CVD).
糖尿病患者冠状动脉疾病风险增加与脂蛋白水平升高有关。通常，在I型糖尿病中，通过抗糖尿病药物控制血糖可降低此类风险。然而，在II型糖尿病中，使用抗糖尿病药物可改善血脂水平，但冠状动脉疾病风险仍然存在。降低糖尿病患者血脂含量的初始方法应包括血糖控制、饮食、减肥和运动。但如果失败，则贝特类药物和HMG CoA还原酶（3-羟基-3-甲基戊二酰辅酶A还原酶）抑制剂等降脂药物应有效。在本研究中，阿托伐他汀与双胍类药物比较的结果证明，阿托伐他汀是一种更有效的降脂药物，同时具有抗糖尿病活性，因此它可以有效帮助降低心血管疾病（CVD）风险。
